# ADMA — AI stock forecast & analysis

> AI-generated analysis by K3vl4r — 2026-07-01. Informational only, not financial advice.

**Recommendation:** HOLD

**Scores (0–100):** Overall 5 · Fundamentals 6.8 · Technicals 4.8 · Growth 7.5 · Risk 7

## Summary

ADMA Biologics faces significant headwinds from a pending securities lawsuit and recent price volatility, but its strong fundamentals (high ROE, positive cash flow) and pipeline products offer long-term upside. The technicals analysis shows a downtrend from $20.45 to current price of $8.37, with resistance at $13.55 and support at $8.38. The Kronos AI forecast suggests continued downward pressure.

## Price targets (24-month horizon)

- Bear: $7.19
- Base: $10.25
- Bull: $17.75

## News context

The securities lawsuit alleging revenue inflation (June 2026) is a critical risk, though analyst sentiment remains bullish with a target of $17.75. Recent price action shows volatility: -4.34% on June 29 and +1.4% on June 23, reflecting market uncertainty. The pipeline's potential for S. pneumonia products offers growth but is overshadowed by legal risks.

## About
- Methodology: https://app.k3vl4r.com/methodology
- Full report: https://app.k3vl4r.com/r/adma-ai-stock-forecast-8be4093a1cfd1a21b3dcf2efaa54cd00
- AI-generated; model outputs can be wrong. Not financial advice.